<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-LAA-2229</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2229</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Липополисахарид и ОРДС, вызванный новой коронавирусной инфекцией: гипотезы и факты</article-title><trans-title-group xml:lang="en"><trans-title>Lipopolysaccharide and ARDS caused by new coronavirus infection: hypotheses and facts</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5486-7262</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яцков</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yatskov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ассистент кафедры внутренней медицины № 2</p><p>295491, Республика Крым, г. Симферополь, пгт Аэрофлотский, ул. Мальченко, 7, кв. 28</p><p>Тел.: 8 (978) 709-40-15.</p></bio><bio xml:lang="en"><p>Assistant Professor, Department of Internal Medicine No. 2</p><p>295491, Republic of Crimea, Simferopol, Aeroflotsky smt, Malchenko str., 7, apt. 28, Phone: 7 (978) 709-40-15</p></bio><email xlink:type="simple">egermd@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9640-754X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белоглазов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Beloglazov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., профессор, заведующий кафедрой внутренней медицины № 2</p><p>г. Симферополь, Республика Крым</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Department of Internal Medicine No. 2</p><p>Simferopol, Republic of Crimea</p></bio><email xlink:type="simple">biloglazov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3187-220X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ряпова</surname><given-names>Э. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryapova</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Студентка кафедры внутренней медицины № 2</p><p>г. Симферополь, Республика Крым</p></bio><bio xml:lang="en"><p>Student, Department of Internal Medicine No. 2</p><p>Simferopol, Republic of Crimea</p></bio><email xlink:type="simple">elvina.ryapova@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинская академия имени С. И. Георгиевского – структурное подразделение ФГАОУ ВО «Крымский федеральный университет имени В. И. Вернадского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S. Georgievsky Medical Academy, V. Vernadsky Crimean Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Медицинская академия имени С.И. Георгиевского – структурное подразделение ФГАОУ ВО «Крымский федеральный университет имени В. И. Вернадского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S. Georgievsky Medical Academy, V. Vernadsky Crimean Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>03</month><year>2022</year></pub-date><volume>24</volume><issue>1</issue><fpage>7</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Яцков И.А., Белоглазов В.А., Ряпова Э.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Яцков И.А., Белоглазов В.А., Ряпова Э.И.</copyright-holder><copyright-holder xml:lang="en">Yatskov I.A., Beloglazov V.A., Ryapova E.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2229">https://www.mimmun.ru/mimmun/article/view/2229</self-uri><abstract><p>В данном обзоре представлены данные из литературных источников, которые дают представление о роли липополисахарида (LPS) грамнегативной флоры в патогенезе острого респираторного дистресс-синдрома (ОРДС), вызванного новой коронавирусной инфекцией SARS-CoV-2. ОРДС – это синдром тяжелой недостаточности дыхания, остро возникающее диффузное воспалительное поражение легких, развивающееся как неспецифическая реакция на различные прямые (аспирация, ингаляция токсичных газов) и системные (сепсис, политравма) повреждающие факторы и приводящее к формированию острой дыхательной недостаточности (ОДН) вследствие нарушения структуры паренхимы легких, нарушения сосудистой проницаемости, уменьшения площади вентилируемой легочной ткани.</p><p>ОРДС при коронавирусной инфекции, по-видимому, имеет худшие результаты, чем ОРДС, вызванный другими причинами. Смертность в отделении интенсивной терапии и больнице от типичного ОРДС составляет 35,3% и 40,0% соответственно, тогда как для вызванного COVID-19 ОРДС смертность варьировалась от 26% до 61,5%, а у пациентов, которым была проведена искусственная вентиляция легких, смертность может колебаться от 65,7% до 94%. Факторы риска неблагоприятных исходов включают пожилой возраст; наличие сопутствующих заболеваний, таких как гипертония, сердечно-сосудистые заболевания и сахарный диабет; снижение количества лимфоцитов; травма почек; и повышенный уровень D-димера. Смерть от ОРДС при COVID-19 наступает в результате дыхательной недостаточности (53%), дыхательной недостаточности в сочетании с сердечной недостаточностью (33%), повреждения миокарда и недостаточности кровообращения (7%) или смерти по неизвестной причине.</p><p>Большое количество исследований показывают, что ЛПС прямо или косвенно участвует во всех патогенетических звеньях ОРДС, вызванного вирусом SARS-CoV-2, а именно: ухудшает течение воспалительных заболеваний легких на фоне снижения уровня ангиотензинпревращающего фермента 2 (ACE2); увеличивает генерацию активных форм кислорода (АФК) посредством НАДФН-оксидазы и последующую дезактивацию эндотелиальной синтазы оксида азота (eNOS) и снижение биодоступности эндотелиального NO, что приводит к эндотелиальной дисфункции; взаимодействует с белками сурфактантов. SP-A и SP-D, способствуя раннему разрушению монослоя и снижению поверхностного натяжения; взаимодействует с растворимой формой CD14-рецептора, что также оказывает провоспалительное воздействие на эпителиальные и эндотелиальные клетки; через рецепторы TLR4 приводит к активации p38MAPK, деградации белка IêBá и последующей транслокации p65 NF-êB в ядро, что приводит к транскрипции IL-6 и молекул адгезии (ICAM-1, VCAM-1 и E-селектин); а также, как показано в исследовании Petruk и соавт. (2020), непосредственно связываясь с S-белком вируса в сочетании с LPS усиливает активацию ядерного факторакаппа B (NF-êB) в моноцитарных клетках THP- 1 и цитокиновые ответы в мононуклеарных клетках крови. Данные патофизиологические механизмы требуют дальнейшего глубокого изучения с целью понимания природы изменений, возникающих на фоне новой коронавирусной инфекции SARS-CoV-2.</p></abstract><trans-abstract xml:lang="en"><p>This review presents data from the literature that provide insight into the role of the lipopolysaccharide (LPS) of the Gram-negative bacteria in pathogenesis of acute respiratory distress syndrome (ARDS) caused by the novel SARS-CoV-2 coronavirus infection. ARDS is a syndrome of severe respiratory failure, an acutely occurring diffuse inflammatory lesion of lung tissue that develops as a nonspecific reaction to various direct (aspiration, inhalation of toxic gases), and systemic (sepsis, polytrauma) damaging factors and leading to development of acute respiratory failure (ARF), due to impaired structure of the lung parenchyma, disturbances in vascular permeability, decreased area of ventilated lung tissue. ARDS from coronavirus infection appears to have worse outcomes than ARDS from other causes. Mortality from typical ARDS at the intensive care units and hospitals is 35.3% and 40.0%, respectively, while the lethality rates for COVID-19-associated ARDS, ranged from 26% to 61.5%. Among patients who underwent artificial ventilation of the lungs, the mortality rates can range from 65.7% to 94%. Risk factors for poor outcomes include, e.g., older age, presence of concomitant diseases such as hypertension, cardiovascular disease and diabetes mellitus; decreased number of lymphocytes, kidney injury, and increased D-dimer levels. Death with ARDS in COVID-19 occurs as a result of respiratory failure (53%), respiratory failure combined with heart failure (33%), myocardial damage and circulatory failure (7%), or death from an unknown cause. A large number of studies show that bacterial LPS is directly or indirectly involved in all pathogenetic links of ARDS caused by the SARS-CoV-2 virus, i.e., worsening the course of inflammatory lung diseases due to decreased level of angiotensin-converting enzyme 2 (ACE2); increasing generation of reactive oxygen species (ROS) via NADPH oxidase and subsequent inactivation of endothelial nitric oxide synthase (eNOS) and decreasing bioavailability of endothelial NO, thus leading to endothelial dysfunction; interacting with proteins of surfactants. SP-A and SP-D, promoting early destruction of the cellular monolayers and lowering surface tension, interact with soluble CD14 receptor, which also has a pro-inflammatory effect on epithelial and endothelial cells, leading to p38MAPK activation via TLR4 receptors, causing degradation of IêBá protein and subsequent translocation of p65 NF-êB into the nucleus, thus inducing transcription of IL-6 and adhesion molecules (ICAM-1, VCAM-1 and E-selectin), and, as shown by Petruk et al. (2020), causing direct binding to the viral S protein in combination with LPS, thus enhancing activation of nuclear factor-kappa B (NF-êB) in monocytic THP-1 cells and cytokine responses in mononuclear blood cells. These pathophysiological mechanisms require further in-depth study in order to understand the nature of changes that occur in the patients with new SARS-CoV-2 infection.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>LPS</kwd><kwd>ОРДС</kwd><kwd>коронавирус</kwd><kwd>эндотоксин</kwd><kwd>воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>LPS</kwd><kwd>ARDS</kwd><kwd>coronavirus</kwd><kwd>endotoxin</kwd><kwd>inflammation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Белоглазов В.А., Яцков И.А. Роль катепсина G в патогенезе хронической обструктивной болезни легких: возможные пути регуляции // Медицинская иммунология, 2020. Т. 22, № 3. С. 443-448. doi: 10.15789/1563-0625-ROC-1769.</mixed-citation><mixed-citation xml:lang="en">Beloglazov V.A., Yatskov I.A. Role of сathepsin G in pathogenesis of chronic obstructive lung disease: possible ways of regulation. Meditsinskaya immunologiya = Medical Immunology (Russia), 2020, Vol. 22, no. 3, p. 443-448. (In Russ.) doi: 10.15789/1563-0625-ROC-1769.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Заболотских И.Б., Шифман Е.М. Анестезиология-реаниматология. Клинические рекомендации. М.: ГЭОТАР-Медиа, 2016. 960 с.</mixed-citation><mixed-citation xml:lang="en">Zabolotskikh I.B., Shifman E.M. Anesthesiology – resuscitation science: clinical guidelines. Moscow: GEOTAR-Media, 2016. 960 p.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Конев Ю.В. Роль эндотоксина (ЛПС) в патогенезе метаболического синдрома и атеросклероза // Экспериментальная и клиническая гастроэнтерология, 2012. № 11. С. 11-22.</mixed-citation><mixed-citation xml:lang="en">Konev Yu.V. The role of endotoxin in pathogenesis of metabolic syndrome and atherosclerosis. Eksperimentalnaya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology, 2012, no. 11, p. 11-22. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Миллер Р. Анестезия Рональда Миллера: руководство в 4-х томах. СПб.: Человек, 2015. 3328 c.</mixed-citation><mixed-citation xml:lang="en">Miller R. Ronald Miller’s Anesthesiology. St. Petersburg: Chelovek, 2015. 3328 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Рябов Г.Л. Гипоксия критических состояний. М.: Медицина, 1988. 288 с.</mixed-citation><mixed-citation xml:lang="en">Ryabov G.L. Hypoxia of critical conditions. Moscow: Meditsina, 1988. 288 p.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Akira S., Uematsu S., Takeuchi O. Pathogen Recognition and Innate Immunity. Cell, 2006, Vol. 124, no. 4, pp. 783-801.</mixed-citation><mixed-citation xml:lang="en">Akira S., Uematsu S., Takeuchi O. Pathogen Recognition and Innate Immunity. Cell, 2006, Vol. 124, no. 4, pp. 783-801.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Alenina N., Bader M. ACE2 in bvrain physiology and pathophysiology: evidence from transgenic animal models. Neurochem. Res., 2019, Vol. 44, no. 6, pp. 1323-1329.</mixed-citation><mixed-citation xml:lang="en">Alenina N., Bader M. ACE2 in bvrain physiology and pathophysiology: evidence from transgenic animal models. Neurochem. Res., 2019, Vol. 44, no. 6, pp. 1323-1329.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Belančić A., Jovanović G.K., Majanović S.K. Obesity-related low-grade chronic inﬂammation: implementation of the dietary inﬂammatory index in clinical practice is the milestone? Medicina Fluminensis, 2018, Vol. 54, no. 4, pp. 373-378.</mixed-citation><mixed-citation xml:lang="en">Belančić A., Jovanović G.K., Majanović S.K. Obesity-related low-grade chronic inﬂammation: implementation of the dietary inﬂammatory index in clinical practice is the milestone? Medicina Fluminensis, 2018, Vol. 54, no. 4, pp. 373-378.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Belančić A. Gut microbiome dysbiosis and endotoxemia – Additional pathophysiological explanation for increased COVID-19 severity in obesity. Obes. Med., 2020, Vol. 20, 100302. doi: 10.1016/j.obmed.2020.100302.</mixed-citation><mixed-citation xml:lang="en">Belančić A. Gut microbiome dysbiosis and endotoxemia – Additional pathophysiological explanation for increased COVID-19 severity in obesity. Obes. Med., 2020, Vol. 20, 100302. doi: 10.1016/j.obmed.2020.100302.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bellani G., Laﬀey J.G., Pham T. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA, 2016, Vol. 315, pp. 788-800.</mixed-citation><mixed-citation xml:lang="en">Bellani G., Laﬀey J.G., Pham T. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA, 2016, Vol. 315, pp. 788-800.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Blakeway L.V., Tan A., Peak R.A., Seib K.L. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development. Microbiology, 2017, Vol. 163, pp. 1371-1384.</mixed-citation><mixed-citation xml:lang="en">Blakeway L.V., Tan A., Peak R.A., Seib K.L. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development. Microbiology, 2017, Vol. 163, pp. 1371-1384.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Buﬂer P., Schmidt B., Schikor D., Bauernfeind A., Crouch E.C., Griese M. Surfactant protein A and D diﬀerently regulate the immune response to nonmucoid Pseudomonas aeruginosa and its lipopolysaccharide. Am. J. Respir. Cell Mol. Biol., 2003, Vol. 28, pp. 249-256.</mixed-citation><mixed-citation xml:lang="en">Buﬂer P., Schmidt B., Schikor D., Bauernfeind A., Crouch E.C., Griese M. Surfactant protein A and D diﬀerently regulate the immune response to nonmucoid Pseudomonas aeruginosa and its lipopolysaccharide. Am. J. Respir. Cell Mol. Biol., 2003, Vol. 28, pp. 249-256.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cañadas O., Keough K.M., Casals C. Bacterial lipopolysaccharide promotes destabilization of lung surfactant-like ﬁlms. Biophys. J., 2011, Vol. 100, no. 1, pp. 108-116.</mixed-citation><mixed-citation xml:lang="en">Cañadas O., Keough K.M., Casals C. Bacterial lipopolysaccharide promotes destabilization of lung surfactant-like ﬁlms. Biophys. J., 2011, Vol. 100, no. 1, pp. 108-116.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Choi K.J., Cha S.I., Shin K. M., Lee J., Hwangbo Y., Yoo S.S., Lee J., Lee S.Y., Kim C.H., Park J.Y. Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration, 2013, Vol. 85, no. 3, pp. 203-209.</mixed-citation><mixed-citation xml:lang="en">Choi K.J., Cha S.I., Shin K. M., Lee J., Hwangbo Y., Yoo S.S., Lee J., Lee S.Y., Kim C.H., Park J.Y. Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration, 2013, Vol. 85, no. 3, pp. 203-209.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chroneos Z.C., Sever-Chroneos Z., Shepherd V.L. Pulmonary surfactant: an immunological perspective. Cell. Physiol. Biochem., 2010, Vol. 25, no. 1, pp. 13-26.</mixed-citation><mixed-citation xml:lang="en">Chroneos Z.C., Sever-Chroneos Z., Shepherd V.L. Pulmonary surfactant: an immunological perspective. Cell. Physiol. Biochem., 2010, Vol. 25, no. 1, pp. 13-26.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Curstedt T., Calkovska A., Johansson J. New generation synthetic surfactants. Neonatology, 2013, Vol. 103, no. 4, pp. 327-330.</mixed-citation><mixed-citation xml:lang="en">Curstedt T., Calkovska A., Johansson J. New generation synthetic surfactants. Neonatology, 2013, Vol. 103, no. 4, pp. 327-330.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Curstedt T., Johansson J. Diﬀerent eﬀects of surfactant proteins B and C – implications for development of synthetic surfactants. Neonatology, 2010, Vol. 97, no. 4, pp. 367-372.</mixed-citation><mixed-citation xml:lang="en">Curstedt T., Johansson J. Diﬀerent eﬀects of surfactant proteins B and C – implications for development of synthetic surfactants. Neonatology, 2010, Vol. 97, no. 4, pp. 367-372.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Di Lorenzo F., Palmigiano A., Al Bitar-Nehme S. The lipid A from rhodopseudomonas palustris strain bisa53 lps possesses a unique structure and low immunostimulant properties. Chemistry, 2017, Vol. 23, no. 15, pp. 3637-3647.</mixed-citation><mixed-citation xml:lang="en">Di Lorenzo F., Palmigiano A., Al Bitar-Nehme S. The lipid A from rhodopseudomonas palustris strain bisa53 lps possesses a unique structure and low immunostimulant properties. Chemistry, 2017, Vol. 23, no. 15, pp. 3637-3647.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Dickson R.P., Schultz M.J., Poll T.V., Schouten L.R., Falkowski N.R., Luth J.E., Sjoding M.W., Brown C.A., Chanderraj R., Huﬀnagle G.B. Biomarker Analysis in Septic ICU Patients (BASIC) Consortium. Lung microbiota predict clinical outcomes in critically ill Patients. Am. J. Respir. Crit. Care Med., 2020, Vol. 201, no. 5, pp. 555-563.</mixed-citation><mixed-citation xml:lang="en">Dickson R.P., Schultz M.J., Poll T.V., Schouten L.R., Falkowski N.R., Luth J.E., Sjoding M.W., Brown C.A., Chanderraj R., Huﬀnagle G.B. Biomarker Analysis in Septic ICU Patients (BASIC) Consortium. Lung microbiota predict clinical outcomes in critically ill Patients. Am. J. Respir. Crit. Care Med., 2020, Vol. 201, no. 5, pp. 555-563.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Echaide M., Autilio C., Arroyo R., Perez-Gil J. Restoring pulmonary surfactant membranes and ﬁlms at the respiratory surface. Biochim. Biophys. Acta Biomembr., 2017, Vol. 1859, no. 9, Pt B, pp. 1725-1739.</mixed-citation><mixed-citation xml:lang="en">Echaide M., Autilio C., Arroyo R., Perez-Gil J. Restoring pulmonary surfactant membranes and ﬁlms at the respiratory surface. Biochim. Biophys. Acta Biomembr., 2017, Vol. 1859, no. 9, Pt B, pp. 1725-1739.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Einarsson G.G., Comer D.M., Mcilreavey L., Parkhill J., Ennis M., Tunney M.M., Elborn J.S. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax, 2016, Vol. 71, no. 9, pp. 795-803.</mixed-citation><mixed-citation xml:lang="en">Einarsson G.G., Comer D.M., Mcilreavey L., Parkhill J., Ennis M., Tunney M.M., Elborn J.S. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax, 2016, Vol. 71, no. 9, pp. 795-803.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Engelmann B., Massberg S. Thrombosis as an intravascular eﬀector of innate immunity. Nat. Rev. Immunol., 2013 Vol. 13, no. 1, pp. 34-45.</mixed-citation><mixed-citation xml:lang="en">Engelmann B., Massberg S. Thrombosis as an intravascular eﬀector of innate immunity. Nat. Rev. Immunol., 2013 Vol. 13, no. 1, pp. 34-45.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Erb-Downward J.R., Thompson D.L., Han M.K., Freeman C.M., McCloskey L., Schmidt L.A., Young V.B., Toews G.B., Curtis J.L., Sundaram B. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One, 2011, Vol. 6, no. 2, e16384. doi: 10.1371/journal.pone.0016384.</mixed-citation><mixed-citation xml:lang="en">Erb-Downward J.R., Thompson D.L., Han M.K., Freeman C.M., McCloskey L., Schmidt L.A., Young V.B., Toews G.B., Curtis J.L., Sundaram B. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One, 2011, Vol. 6, no. 2, e16384. doi: 10.1371/journal.pone.0016384.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Eriksson O., Hultström M., Persson B., Lipcsey M., Ekdahl K.N., Nilsson B., Frithiof R. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb. Haemost., 2020, Vol. 120, no. 12, pp. 1720-1724.</mixed-citation><mixed-citation xml:lang="en">Eriksson O., Hultström M., Persson B., Lipcsey M., Ekdahl K.N., Nilsson B., Frithiof R. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb. Haemost., 2020, Vol. 120, no. 12, pp. 1720-1724.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fan V.S., Gharib S.A., Martin T.R. Wurfel M.M. COPD disease severity and innate immune response to pathogen-associated molecular patterns. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, Vol. 11, pp. 467-477.</mixed-citation><mixed-citation xml:lang="en">Fan V.S., Gharib S.A., Martin T.R. Wurfel M.M. COPD disease severity and innate immune response to pathogen-associated molecular patterns. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, Vol. 11, pp. 467-477.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Galdeano C.M., Cazorla S.I., Lemme Dumit J.M., Vélez E., Perdigón G. Beneﬁcial eﬀects of probiotic consumption on the immune system. Ann. Nutr. Metab., 2019, Vol. 74, no. 2, pp. 115-124.</mixed-citation><mixed-citation xml:lang="en">Galdeano C.M., Cazorla S.I., Lemme Dumit J.M., Vélez E., Perdigón G. Beneﬁcial eﬀects of probiotic consumption on the immune system. Ann. Nutr. Metab., 2019, Vol. 74, no. 2, pp. 115-124.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gallo M.C., Kirkham C., Eng S., Bebawee R.S., Kong Y., Pettigrew M.M., Tettelin H., Murphy T.F. Changes in IgA protease expression are conferred by changes in genomes during persistent Infection by nontypeable Haemophilus inﬂuenzae in chronic obstructive pulmonary disease. Infect. Immun., 2018, Vol. 86, no. 8, e00313-18. doi: 10.1128/IAI.00313-18.</mixed-citation><mixed-citation xml:lang="en">Gallo M.C., Kirkham C., Eng S., Bebawee R.S., Kong Y., Pettigrew M.M., Tettelin H., Murphy T.F. Changes in IgA protease expression are conferred by changes in genomes during persistent Infection by nontypeable Haemophilus inﬂuenzae in chronic obstructive pulmonary disease. Infect. Immun., 2018, Vol. 86, no. 8, e00313-18. doi: 10.1128/IAI.00313-18.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gardai S.J., Xiao Y.Q., Dickinson M., Nick J.A., Voelker D.R., Greene K.E., Henson P.M. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inﬂammation. Cell, 2003, Vol. 115, no. 1, pp. 13-23.</mixed-citation><mixed-citation xml:lang="en">Gardai S.J., Xiao Y.Q., Dickinson M., Nick J.A., Voelker D.R., Greene K.E., Henson P.M. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inﬂammation. Cell, 2003, Vol. 115, no. 1, pp. 13-23.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gibson P.G., Qin L., Puah S.H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and diﬀerences from typical pre-COVID-19 ARDS. Med. J. Aust., 2020, Vol. 213, no. 2, pp. 54-56.</mixed-citation><mixed-citation xml:lang="en">Gibson P.G., Qin L., Puah S.H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and diﬀerences from typical pre-COVID-19 ARDS. Med. J. Aust., 2020, Vol. 213, no. 2, pp. 54-56.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Grylls A., Seidler K., Neil J. Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inﬂammation, and therapeutic implication of probiotics. Biomed. Pharmacother., 2021, Vol. 137, 111334. doi: 10.1016/j.biopha.2021.111334.</mixed-citation><mixed-citation xml:lang="en">Grylls A., Seidler K., Neil J. Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inﬂammation, and therapeutic implication of probiotics. Biomed. Pharmacother., 2021, Vol. 137, 111334. doi: 10.1016/j.biopha.2021.111334.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Hennezel E., Abubucker S., Murphy L.O., Cullen T.W. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. Systems, 2017, Vol. 2, no. 6, e00046-17. doi: 10.1128/mSystems.00046-17e00046-17.</mixed-citation><mixed-citation xml:lang="en">Hennezel E., Abubucker S., Murphy L.O., Cullen T.W. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. Systems, 2017, Vol. 2, no. 6, e00046-17. doi: 10.1128/mSystems.00046-17e00046-17.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hoel H., Heggelund L., Reikvam D.H., Stiksrud B., Ueland T., Michelsen A.E., Otterdal K., Muller K.E., Lind A., Muller F., Dudman S., Aukrust P., Dyrhol-Riise A.M., Holter J.C., Troseid M. Elevated markers of gut leakage and inﬂammasome activation in COVID-19 patients with cardiac involvement. J. Intern. Med., 2020, Vol.25, no. 10, joim.13178. doi: 10.1111/joim.13178.</mixed-citation><mixed-citation xml:lang="en">Hoel H., Heggelund L., Reikvam D.H., Stiksrud B., Ueland T., Michelsen A.E., Otterdal K., Muller K.E., Lind A., Muller F., Dudman S., Aukrust P., Dyrhol-Riise A.M., Holter J.C., Troseid M. Elevated markers of gut leakage and inﬂammasome activation in COVID-19 patients with cardiac involvement. J. Intern. Med., 2020, Vol.25, no. 10, joim.13178. doi: 10.1111/joim.13178.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Holmskov U., Thiel S., Jensenius J.C. Collections and ﬁcolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol., 2003, Vol. 21, pp. 547-578.</mixed-citation><mixed-citation xml:lang="en">Holmskov U., Thiel S., Jensenius J.C. Collections and ﬁcolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol., 2003, Vol. 21, pp. 547-578.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Hou H.H., Wang H.C., Cheng S.L., Chen Y.F., K.Z. Lu, Yu C.J. MMP-12 activates protease-activated receptor-1, upregulates placenta growth factor, and leads to pulmonary emphysema. Am. J. Physiol. Lung Cell. Mol. Physiol., 2018, Vol. 315, no. 3, pp. L432-L442.</mixed-citation><mixed-citation xml:lang="en">Hou H.H., Wang H.C., Cheng S.L., Chen Y.F., K.Z. Lu, Yu C.J. MMP-12 activates protease-activated receptor-1, upregulates placenta growth factor, and leads to pulmonary emphysema. Am. J. Physiol. Lung Cell. Mol. Physiol., 2018, Vol. 315, no. 3, pp. L432-L442.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y.J., Kim E., Cox M.J., Brodie E.L., Brown R., Wiener-Kronish J.P., Lynch S.V. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS, 2010, Vol. 14, no. 1, pp. 9-59.</mixed-citation><mixed-citation xml:lang="en">Huang Y.J., Kim E., Cox M.J., Brodie E.L., Brown R., Wiener-Kronish J.P., Lynch S.V. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS, 2010, Vol. 14, no. 1, pp. 9-59.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Koliada A., Syzenko G., Moseiko V. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol., 2017, Vol. 17, no. 1, 120. doi: 10.1186/s12866-017-1027-1.</mixed-citation><mixed-citation xml:lang="en">Koliada A., Syzenko G., Moseiko V. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol., 2017, Vol. 17, no. 1, 120. doi: 10.1186/s12866-017-1027-1.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kramer C.D., Genco C.A. Microbiota, immune subversion, and chronic inﬂammation. Front. Immunol., Vol. 8, 255. doi: 10.3389/ﬁmmu.2017.00255.</mixed-citation><mixed-citation xml:lang="en">Kramer C.D., Genco C.A. Microbiota, immune subversion, and chronic inﬂammation. Front. Immunol., Vol. 8, 255. doi: 10.3389/ﬁmmu.2017.00255.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Lei X., Dong X., Ma R. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun., 2020, Vol. 11, no. 1, 3810. doi: 10.1038/s41467-020-17665-9.</mixed-citation><mixed-citation xml:lang="en">Lei X., Dong X., Ma R. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun., 2020, Vol. 11, no. 1, 3810. doi: 10.1038/s41467-020-17665-9.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Li X.Y., He C., Zhu Y. Role of gut microbiota on intestinal barrier function in acute pancreatitis. World J. Gastroenterol., 202, Vol. 26, no. 18, pp. 2187-2193.</mixed-citation><mixed-citation xml:lang="en">Li X.Y., He C., Zhu Y. Role of gut microbiota on intestinal barrier function in acute pancreatitis. World J. Gastroenterol., 202, Vol. 26, no. 18, pp. 2187-2193.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Lu Y.C., Yen W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine, 2008, Vol. 42, pp. 145-151.</mixed-citation><mixed-citation xml:lang="en">Lu Y.C., Yen W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine, 2008, Vol. 42, pp. 145-151.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Luo S., Zhang X., Xu H. Don’t overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clin. Gastroenterol. Hepatol., 2020, Vol. 18, pp. 1632-1633.</mixed-citation><mixed-citation xml:lang="en">Luo S., Zhang X., Xu H. Don’t overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clin. Gastroenterol. Hepatol., 2020, Vol. 18, pp. 1632-1633.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmoud I.S., Jarrar Y.B., Alshaer W. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. Biochimie, 2020, Vol. 175, pp. 93-98.</mixed-citation><mixed-citation xml:lang="en">Mahmoud I.S., Jarrar Y.B., Alshaer W. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. Biochimie, 2020, Vol. 175, pp. 93-98.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">McGuinness A.J., Sapey E. Oxidative stress in COPD: sources, markers, and potential mechanisms. J. Clin. Med., 2017, Vol. 6, no. 2, 21. doi: 10.3390/jcm6020021.</mixed-citation><mixed-citation xml:lang="en">McGuinness A.J., Sapey E. Oxidative stress in COPD: sources, markers, and potential mechanisms. J. Clin. Med., 2017, Vol. 6, no. 2, 21. doi: 10.3390/jcm6020021.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Miller R. Miller’s Anesthesia, 6th Edition. New York: Churchill Livingston, 2005. 3198 p.</mixed-citation><mixed-citation xml:lang="en">Miller R. Miller’s Anesthesia, 6th Edition. New York: Churchill Livingston, 2005. 3198 p.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Moﬀatt M.F., Cookson W.O. The lung microbiome in health and disease. Clin. Med., 2017, Vol. 17, pp. 525-529.</mixed-citation><mixed-citation xml:lang="en">Moﬀatt M.F., Cookson W.O. The lung microbiome in health and disease. Clin. Med., 2017, Vol. 17, pp. 525-529.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Molinaro A., Holst O., Di Lorenzo F. Chemistry of lipid A: At the heart of innate immunity. Chem. Eur. J., 2015, Vol. 21, pp. 500-519.</mixed-citation><mixed-citation xml:lang="en">Molinaro A., Holst O., Di Lorenzo F. Chemistry of lipid A: At the heart of innate immunity. Chem. Eur. J., 2015, Vol. 21, pp. 500-519.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Moreira A.P., Texeira T.F., Ferreira A.B., Peluzio M., Alfenas R.C. Inﬂuence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxemia. Br. J. Nutr., Vol. 108, no. 5, pp. 801-809.</mixed-citation><mixed-citation xml:lang="en">Moreira A.P., Texeira T.F., Ferreira A.B., Peluzio M., Alfenas R.C. Inﬂuence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxemia. Br. J. Nutr., Vol. 108, no. 5, pp. 801-809.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Munford R.S. Sensing Gram-Negative Bacterial Lipopolysaccharides: a Human Disease Determinant? Infect. Immun., 2008, Vol. 76, pp. 454-465.</mixed-citation><mixed-citation xml:lang="en">Munford R.S. Sensing Gram-Negative Bacterial Lipopolysaccharides: a Human Disease Determinant? Infect. Immun., 2008, Vol. 76, pp. 454-465.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Nagpal R., Newman T.M., Wang S., Jain S., Lovato J.F., Yadav H. Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J. Diabetes Res., 2018, Vol. 2018, 3462092. doi: 10.1155/2018/3462092.</mixed-citation><mixed-citation xml:lang="en">Nagpal R., Newman T.M., Wang S., Jain S., Lovato J.F., Yadav H. Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J. Diabetes Res., 2018, Vol. 2018, 3462092. doi: 10.1155/2018/3462092.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev., 2003, Vol. 67, pp. 593-656.</mixed-citation><mixed-citation xml:lang="en">Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev., 2003, Vol. 67, pp. 593-656.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Noris M., Benigni A., Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int., 2020, Vol. 98, no. 2, pp. 314-322.</mixed-citation><mixed-citation xml:lang="en">Noris M., Benigni A., Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int., 2020, Vol. 98, no. 2, pp. 314-322.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 2009, Vol. 458, pp. 1191-1195.</mixed-citation><mixed-citation xml:lang="en">Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 2009, Vol. 458, pp. 1191-1195.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Petruk G., Puthia M., Petrlova J., Strömdahl A., Kjellström S., Schmidtchen A. SARS-CoV-2 Spike protein binds to bacterial lipopolysaccharide and boosts proinﬂammatory activity. J. Mol. Cell Biol., 2021, Vol. 12, no. 12, pp. 916-932.</mixed-citation><mixed-citation xml:lang="en">Petruk G., Puthia M., Petrlova J., Strömdahl A., Kjellström S., Schmidtchen A. SARS-CoV-2 Spike protein binds to bacterial lipopolysaccharide and boosts proinﬂammatory activity. J. Mol. Cell Biol., 2021, Vol. 12, no. 12, pp. 916-932.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Popkin B.M., Du S., Green W.D. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes. Rev., 2020, Vol. 71, no. 15, pp. 896-897.</mixed-citation><mixed-citation xml:lang="en">Popkin B.M., Du S., Green W.D. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes. Rev., 2020, Vol. 71, no. 15, pp. 896-897.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Pragman A.A., Knutson K.A., Gould T.J., Isaacson R.E., Reilly C.S., Wendt C.H. Chronic obstructive pulmonary disease upper airway microbiota alpha diversity is associated with exacerbation phenotype: a case-control observational study. Respir. Res., 2019, Vol. 20, 114. doi: 10.1186/s12931-019-1080-4.</mixed-citation><mixed-citation xml:lang="en">Pragman A.A., Knutson K.A., Gould T.J., Isaacson R.E., Reilly C.S., Wendt C.H. Chronic obstructive pulmonary disease upper airway microbiota alpha diversity is associated with exacerbation phenotype: a case-control observational study. Respir. Res., 2019, Vol. 20, 114. doi: 10.1186/s12931-019-1080-4.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Qin J., Li R., Raes J. A human gut microbial gene catalog established by metagenomic sequencing. Nature, 2010, Vol. 464, no. 7285, pp. 59-65.</mixed-citation><mixed-citation xml:lang="en">Qin J., Li R., Raes J. A human gut microbial gene catalog established by metagenomic sequencing. Nature, 2010, Vol. 464, no. 7285, pp. 59-65.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Ricklin D., Hajishengallis G., Yang K. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol., 2010, Vol. 11, no. 9, pp. 785-797.</mixed-citation><mixed-citation xml:lang="en">Ricklin D., Hajishengallis G., Yang K. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol., 2010, Vol. 11, no. 9, pp. 785-797.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Roos A., Bouwman L.H., Munoz J. Functional characterization of the lectin pathway of complement in human serum. Mol. Immunol., 2003, Vol. 39, pp. 655-668.</mixed-citation><mixed-citation xml:lang="en">Roos A., Bouwman L.H., Munoz J. Functional characterization of the lectin pathway of complement in human serum. Mol. Immunol., 2003, Vol. 39, pp. 655-668.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Russo A.J., Behl B., Banerjee I., Rathinam V. Emerging insights into noncanonical inﬂammasome recognition of microbes. J. Mol. Biol., 2018, Vol. 430, no. 2, pp. 207-216.</mixed-citation><mixed-citation xml:lang="en">Russo A.J., Behl B., Banerjee I., Rathinam V. Emerging insights into noncanonical inﬂammasome recognition of microbes. J. Mol. Biol., 2018, Vol. 430, no. 2, pp. 207-216.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Sethi S., Maloney J., Grove L., Wrona C., Berenson C. S. Airway inﬂammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2006, Vol. 173, pp. 991-998.</mixed-citation><mixed-citation xml:lang="en">Sethi S., Maloney J., Grove L., Wrona C., Berenson C. S. Airway inﬂammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2006, Vol. 173, pp. 991-998.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Sethi S., Sethi R., Eschberger K., Lobbins P., Cai X., Grant B.J., Murphy T.F. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2007, Vol. 176, pp. 356-361.</mixed-citation><mixed-citation xml:lang="en">Sethi S., Sethi R., Eschberger K., Lobbins P., Cai X., Grant B.J., Murphy T.F. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2007, Vol. 176, pp. 356-361.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Sirivongrangson P., Kulvichit W., Payungporn S. Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Med. Exp., 2020, Vol. 8, no. 1, 72. doi: 10.1186/s40635-020-00362-8.</mixed-citation><mixed-citation xml:lang="en">Sirivongrangson P., Kulvichit W., Payungporn S. Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Med. Exp., 2020, Vol. 8, no. 1, 72. doi: 10.1186/s40635-020-00362-8.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Skelly A.N., Sato Y., Kearney S., Honda K. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat. Rev. Immunol., 2019, Vol. 19, pp. 305-323.</mixed-citation><mixed-citation xml:lang="en">Skelly A.N., Sato Y., Kearney S., Honda K. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat. Rev. Immunol., 2019, Vol. 19, pp. 305-323.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y., Prindle T., Fulton W.B., Wang S., McCray P.B., Chappell M., Hackam D.J., Jia H. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg bradykinin/BKB1R axis and facilitates LPS-induced neutrophil inﬁltration. Am. J. Physiol. Lung Cell. Mol. Physiol., 2018, Vol. 314, no. 1, pp. 17-31.</mixed-citation><mixed-citation xml:lang="en">Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y., Prindle T., Fulton W.B., Wang S., McCray P.B., Chappell M., Hackam D.J., Jia H. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg bradykinin/BKB1R axis and facilitates LPS-induced neutrophil inﬁltration. Am. J. Physiol. Lung Cell. Mol. Physiol., 2018, Vol. 314, no. 1, pp. 17-31.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Thomson N.C. Targeting oxidant-dependent mechanisms for the treatment of respiratory diseases and their comorbidities. Curr. Opin. Pharmacol., 2018, Vol. 40, pp. 1-8.</mixed-citation><mixed-citation xml:lang="en">Thomson N.C. Targeting oxidant-dependent mechanisms for the treatment of respiratory diseases and their comorbidities. Curr. Opin. Pharmacol., 2018, Vol. 40, pp. 1-8.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Tian W., Zhang N., Jin R. Immune suppression in the early stage of COVID-19 disease. Nat. Commun., 2020, Vol. 11, no. 1, pp. 58-59.</mixed-citation><mixed-citation xml:lang="en">Tian W., Zhang N., Jin R. Immune suppression in the early stage of COVID-19 disease. Nat. Commun., 2020, Vol. 11, no. 1, pp. 58-59.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">van Eijk L. E., Binkhorst M., Bourgonje A.R., Oﬀringa A.K., Mulder D.J., Bos E.M., Kolundzic N., Abdulle A.E., van der Voort P.H., Olde Rikkert M.G., van der Hoeven J.G., Den Dunnen W.F., Hillebrands J.L., van Goor H. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J. Pathol., 2021, Vol. 254, no. 4, pp. 307-331.</mixed-citation><mixed-citation xml:lang="en">van Eijk L. E., Binkhorst M., Bourgonje A.R., Oﬀringa A.K., Mulder D.J., Bos E.M., Kolundzic N., Abdulle A.E., van der Voort P.H., Olde Rikkert M.G., van der Hoeven J.G., Den Dunnen W.F., Hillebrands J.L., van Goor H. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J. Pathol., 2021, Vol. 254, no. 4, pp. 307-331.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Wang C., Xu J., Yang L., Xu Y., Zhang X., Bai C., Kang J., Ran P., Shen H., Wen F. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, Vol. 391, pp. 1706-1717.</mixed-citation><mixed-citation xml:lang="en">Wang C., Xu J., Yang L., Xu Y., Zhang X., Bai C., Kang J., Ran P., Shen H., Wen F. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, Vol. 391, pp. 1706-1717.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H., Head J., Kosma P., Brade H., Müller-Loennies S., Sheikh S., Mcdonald B., Smith K., Cafarella T., Seaton B., Crouch E. Recognition of heptoses and the inner core of bacterial lipopolysaccharides by surfactant protein D. Biochemistry, 2008, Vol. 47, pp. 710-720.</mixed-citation><mixed-citation xml:lang="en">Wang H., Head J., Kosma P., Brade H., Müller-Loennies S., Sheikh S., Mcdonald B., Smith K., Cafarella T., Seaton B., Crouch E. Recognition of heptoses and the inner core of bacterial lipopolysaccharides by surfactant protein D. Biochemistry, 2008, Vol. 47, pp. 710-720.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss J., Barker J. Diverse pro-inﬂammatory endotoxin recognition systems of mammalian innate immunity. F1000Res, 2018, Vol. 7, F1000 Faculty Rev-516. doi: 10.12688/f1000research.13977.1.</mixed-citation><mixed-citation xml:lang="en">Weiss J., Barker J. Diverse pro-inﬂammatory endotoxin recognition systems of mammalian innate immunity. F1000Res, 2018, Vol. 7, F1000 Faculty Rev-516. doi: 10.12688/f1000research.13977.1.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Wu C., Chen X., Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, Vol. 180, no. 7, pp. 934-943.</mixed-citation><mixed-citation xml:lang="en">Wu C., Chen X., Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, Vol. 180, no. 7, pp. 934-943.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang G., Meredith T.C., Kahne D. On the essentiality of lipopolysaccharide to Gram-negative bacteria. Curr. Opin. Microbiol., 2013, Vol. 16, pp. 779-785.</mixed-citation><mixed-citation xml:lang="en">Zhang G., Meredith T.C., Kahne D. On the essentiality of lipopolysaccharide to Gram-negative bacteria. Curr. Opin. Microbiol., 2013, Vol. 16, pp. 779-785.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H., Kang Z., Gong H., Xu D., Wang J., Li Zh., Li Z., Cui X., Xiao J., Zhan J., Meng T., Zhou W., Liu J., Xu H. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut, 2020, Vol. 69, pp. 1010-1018.</mixed-citation><mixed-citation xml:lang="en">Zhang H., Kang Z., Gong H., Xu D., Wang J., Li Zh., Li Z., Cui X., Xiao J., Zhan J., Meng T., Zhou W., Liu J., Xu H. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut, 2020, Vol. 69, pp. 1010-1018.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
